A 14-Gene Panel for Predicting Colorectal Cancer Recurrence Using Circulating Tumor DNA in Different Testing Conditions.

ABSTRACT: Detecting minimal residual disease after surgery is critical for assessing colorectal cancer recurrence risk. Traditional methods, including histology and carcinoembryonic antigen testing, have limited sensitivity. As circulating tumor DNA has emerged as a promising minimal residual disease biomarker, we evaluated circulating tumor DNA detection using a sensitive, targeted 14-gene panel, the Sysmex Plasma-Safe-SeqS colorectal cancer assay, in resectable colorectal cancer cases. We enrolled 46 Japanese patients with preoperatively diagnosed stage II colorectal cancer who underwent surgery at three institutions. Plasma samples were collected pre- and postoperatively. Tumor-informed, plasma-informed, and tumor-naive Plasma-Safe-SeqS colorectal cancer assays were performed. Patients were follo

SUBMITTER: Hisamatsu Y 

PROVIDER: S-EPMC12400044 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature